• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Model for end-stage liver disease (MELD) score, as a prognostic factor for post-operative morbidity and mortality in cirrhotic patients, undergoing hepatectomy for hepatocellular carcinoma.终末期肝病模型(MELD)评分是预测行肝癌切除术的肝硬化患者术后发病率和死亡率的预后因素。
HPB (Oxford). 2009 Jun;11(4):351-7. doi: 10.1111/j.1477-2574.2009.00067.x.
2
Perioperative risk assessment for hepatocellular carcinoma by using the MELD score.应用 MELD 评分评估肝细胞癌的围手术期风险。
J Gastrointest Surg. 2009 Dec;13(12):2268-75. doi: 10.1007/s11605-009-0977-5. Epub 2009 Aug 7.
3
Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality.肝硬化患者肝细胞癌的肝切除术:终末期肝病模型(MELD)评分可预测围手术期死亡率。
J Gastrointest Surg. 2005 Dec;9(9):1207-15; discussion 1215. doi: 10.1016/j.gassur.2005.09.008.
4
Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis.终末期肝病模型(MELD)评分对肝硬化合并肝细胞癌肝切除术后预后的影响。
Liver Transpl. 2006 Jun;12(6):966-71. doi: 10.1002/lt.20761.
5
Predicting morbidity and mortality after hepatic resection in patients with hepatocellular carcinoma: the role of Model for End-Stage Liver Disease score.预测肝癌患者肝切除术后的发病率和死亡率:终末期肝病模型评分的作用。
World J Surg. 2009 Nov;33(11):2412-9. doi: 10.1007/s00268-009-0202-4.
6
Model for End-stage Liver Disease score fails to predict perioperative outcome after hepatic resection for hepatocellular carcinoma in patients without cirrhosis.终末期肝病模型评分无法预测无肝硬化的肝细胞癌患者肝切除术后的围手术期结局。
Am J Surg. 2008 May;195(5):697-701. doi: 10.1016/j.amjsurg.2007.05.054.
7
Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma.肝癌切除术后肝失代偿相关因素的层次交互作用。
JAMA Surg. 2016 Sep 1;151(9):846-53. doi: 10.1001/jamasurg.2016.1121.
8
RAM score is an effective predictor for early mortality and recurrence after hepatectomy for hepatocellular carcinoma.RAM 评分是预测肝癌肝切除术后早期死亡率和复发的有效指标。
BMC Cancer. 2017 Nov 9;17(1):742. doi: 10.1186/s12885-017-3748-9.
9
Esophageal Cancer Surgery for Patients with Concomitant Liver Cirrhosis: A Single-Center Matched-Cohort Study.伴有肝硬化患者的食管癌手术:一项单中心匹配队列研究
Ann Surg Oncol. 2017 Mar;24(3):763-769. doi: 10.1245/s10434-016-5610-8. Epub 2016 Oct 4.
10
Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis.肝硬化患者肝细胞癌根治性肝切除的疗效
World J Gastrointest Oncol. 2021 May 15;13(5):424-439. doi: 10.4251/wjgo.v13.i5.424.

引用本文的文献

1
Overall survival is comparable between percutaneous radiofrequency ablation and liver resection as first-line therapies for solitary 3-5 cm hepatocellular carcinoma.对于直径3至5厘米的孤立性肝细胞癌,经皮射频消融术和肝切除术作为一线治疗方法,其总生存率相当。
Langenbecks Arch Surg. 2025 Feb 12;410(1):66. doi: 10.1007/s00423-025-03632-9.
2
Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations.肝硬化患者的肌肉浸润性膀胱癌:相关考量综述
Bladder Cancer. 2021 Aug 31;7(3):261-278. doi: 10.3233/BLC-211536. eCollection 2021.
3
Pattern Clustering of Symmetric Regional Cerebral Edema on Brain MRI in Patients with Hepatic Encephalopathy.肝性脑病患者脑MRI上对称区域脑水肿的模式聚类
J Korean Soc Radiol. 2024 Mar;85(2):381-393. doi: 10.3348/jksr.2023.0012. Epub 2024 Mar 26.
4
Postoperative Liver Failure: Definitions, Risk factors, Prediction Models and Prevention Strategies.术后肝功能衰竭:定义、危险因素、预测模型和预防策略。
J Gastrointest Surg. 2023 Nov;27(11):2640-2649. doi: 10.1007/s11605-023-05834-2. Epub 2023 Oct 2.
5
Neutrophil-to-high-density-lipoprotein-cholesterol ratio and mortality among patients with hepatocellular carcinoma.中性粒细胞与高密度脂蛋白胆固醇比值与肝细胞癌患者的死亡率
Front Nutr. 2023 May 5;10:1127913. doi: 10.3389/fnut.2023.1127913. eCollection 2023.
6
Time to surgery is not an oncological risk factor in HCC patients undergoing liver resection.手术时间并不是行肝切除术的 HCC 患者的肿瘤学危险因素。
Langenbecks Arch Surg. 2023 May 10;408(1):187. doi: 10.1007/s00423-023-02922-4.
7
Perioperative management for hepatic resection surgery.肝切除手术的围手术期管理
BJA Educ. 2022 Sep;22(9):357-363. doi: 10.1016/j.bjae.2022.05.002. Epub 2022 Jul 19.
8
Comparative study of indocyanine green (ICG)-R15 and Albumin-Indocyanine Green Evaluation (ALICE) grading system in the prediction of posthepatectomy liver failure and postoperative mortality in patients with hepatic alveolar echinococcosis.肝泡型包虫病患者术后肝衰竭和死亡的预测中吲哚菁绿(ICG)-R15 与白蛋白-吲哚菁绿评估(ALICE)分级系统的对比研究。
BMC Gastroenterol. 2022 Jun 14;22(1):297. doi: 10.1186/s12876-022-02367-x.
9
Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma.肝细胞癌中放射性栓塞后行经动脉化疗栓塞术
Cureus. 2022 Apr 3;14(4):e23783. doi: 10.7759/cureus.23783. eCollection 2022 Apr.
10
A novel online calculator based on albumin-bilirubin and aspartate transaminase-to-platelet ratio index for predicting postoperative morbidity following hepatectomy for hepatocellular carcinoma.一种基于白蛋白-胆红素和天冬氨酸转氨酶与血小板比值指数的新型在线计算器,用于预测肝细胞癌肝切除术后的发病率。
Ann Transl Med. 2020 Dec;8(23):1591. doi: 10.21037/atm-20-1421.

本文引用的文献

1
Biology of hepatocellular carcinoma.肝细胞癌生物学
Ann Surg Oncol. 2008 Apr;15(4):962-71. doi: 10.1245/s10434-007-9730-z. Epub 2008 Jan 31.
2
Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis.终末期肝病模型(MELD)评分对肝硬化合并肝细胞癌肝切除术后预后的影响。
Liver Transpl. 2006 Jun;12(6):966-71. doi: 10.1002/lt.20761.
3
Predictive indices of morbidity and mortality after liver resection.肝切除术后发病和死亡的预测指标。
Ann Surg. 2006 Mar;243(3):373-9. doi: 10.1097/01.sla.0000201483.95911.08.
4
Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality.肝硬化患者肝细胞癌的肝切除术:终末期肝病模型(MELD)评分可预测围手术期死亡率。
J Gastrointest Surg. 2005 Dec;9(9):1207-15; discussion 1215. doi: 10.1016/j.gassur.2005.09.008.
5
Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis.终末期肝病模型(MELD)可预测肝硬化患者非移植手术的死亡率。
Ann Surg. 2005 Aug;242(2):244-51. doi: 10.1097/01.sla.0000171327.29262.e0.
6
The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcome.肝硬化患者腹腔内手术的安全性:终末期肝病模型评分在预测预后方面优于Child-Turcotte-Pugh分级。
Arch Surg. 2005 Jul;140(7):650-4; discussion 655. doi: 10.1001/archsurg.140.7.650.
7
The survival benefit of liver transplantation.肝移植的生存获益。
Am J Transplant. 2005 Feb;5(2):307-13. doi: 10.1111/j.1600-6143.2004.00703.x.
8
Hepatocellular carcinoma: current surgical management.肝细胞癌:当前的外科治疗方法
Gastroenterology. 2004 Nov;127(5 Suppl 1):S248-60. doi: 10.1053/j.gastro.2004.09.039.
9
Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey.一项日本全国性调查中对肝细胞癌患者肝切除术后生存预后因素的重新评估。
Cancer. 2004 Aug 15;101(4):796-802. doi: 10.1002/cncr.20426.
10
Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome.肝细胞癌肝切除术:患者选择与术后结果
Liver Transpl. 2004 Feb;10(2 Suppl 1):S39-45. doi: 10.1002/lt.20040.

终末期肝病模型(MELD)评分是预测行肝癌切除术的肝硬化患者术后发病率和死亡率的预后因素。

Model for end-stage liver disease (MELD) score, as a prognostic factor for post-operative morbidity and mortality in cirrhotic patients, undergoing hepatectomy for hepatocellular carcinoma.

机构信息

Division of Liver and GI Transplantation, University of Miami Miller School of Medicine, Miami, FL, USA.

出版信息

HPB (Oxford). 2009 Jun;11(4):351-7. doi: 10.1111/j.1477-2574.2009.00067.x.

DOI:10.1111/j.1477-2574.2009.00067.x
PMID:19718364
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2727090/
Abstract

BACKGROUND/AIMS: To evaluate the ability of the model for end-stage liver disease (MELD) in predicting the post-hepatectomy outcome for hepatocellular carcinoma (HCC).

METHODS

Between 2001 and 2004, 69 cirrhotic patients with HCC underwent hepatectomy and the results were retrospectively analysed. MELD score was associated with post-operative mortality and morbidity, hospital stay and 3-year survival.

RESULTS

Seventeen major and 52 minor resections were performed. Thirty-day mortality rate was 7.2%. MELD < or = 9 was associated with no peri-operative mortality vs. 19% when MELD > 9 (P < 0.02). Overall morbidity rate was 36.23%; 48% when MELD > 9 vs. 25% when MELD < or = 9 (P < 0.02). Median hospital stay was 12 days [8.8 days, when MELD < or = 9 and 15.6 days when MELD > 9 (P = 0.037)]. Three-year survival reached 49% (66% when MELD < or = 9; 32% when MELD > 9 (P < 0.01). In multivariate analysis, MELD > 9 (P < 0.01), clinical tumour symptoms (P < 0.05) and American Society of Anesthesiologists (ASA) score (P < 0.05) were independent predictors of peri-operative mortality; MELD > 9 (P < 0.01), tumour size >5 cm (P < 0.01), high tumour grade (P = 0.01) and absence of tumour capsule (P < 0.01) were independent predictors of decreased long-term survival.

CONCLUSION

MELD score seems to predict outcome of cirrhotic patients with HCC, after hepatectomy.

摘要

背景/目的:评估终末期肝病模型(MELD)预测肝细胞癌(HCC)肝切除术后结局的能力。

方法

2001 年至 2004 年间,69 例肝硬化合并 HCC 的患者接受了肝切除术,回顾性分析了这些患者的结果。MELD 评分与术后死亡率和发病率、住院时间和 3 年生存率相关。

结果

17 例为大切除术,52 例为小切除术。30 天死亡率为 7.2%。MELD <或= 9 与无围手术期死亡相关,而 MELD > 9 时为 19%(P < 0.02)。总发病率为 36.23%;MELD > 9 时为 48%,MELD <或= 9 时为 25%(P < 0.02)。中位住院时间为 12 天[MELD <或= 9 时为 8.8 天,MELD > 9 时为 15.6 天(P = 0.037)]。3 年生存率达到 49%(MELD <或= 9 时为 66%,MELD > 9 时为 32%(P < 0.01))。多变量分析显示,MELD > 9(P < 0.01)、临床肿瘤症状(P < 0.05)和美国麻醉医师协会(ASA)评分(P < 0.05)是围手术期死亡率的独立预测因素;MELD > 9(P < 0.01)、肿瘤直径>5 cm(P < 0.01)、肿瘤分级高(P = 0.01)和无肿瘤包膜(P < 0.01)是降低长期生存率的独立预测因素。

结论

MELD 评分似乎可以预测肝硬化合并 HCC 患者肝切除术后的结局。